poisar

Stocks · News reference

InspireMD Q2 EPS $(0.17) Beats $(0.19) Estimate, Sales $1.771M Miss $2.133M Estimate

Benzinga Newsdesk

InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 34.62 percent increase over losses of $(0.26) per share from the

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NSPR
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million

    InspireMD amended Series J and K warrants affecting approximately 14.3 million shares, aligning the exercise trigger with anticipated FDA approval of CGuard Prime 80 cm expected in Q4 2026. The amendments could provide up to $11 million in gross proceeds to fund the commercial launch of the TCAR product, which targets an addressable market of over 35,000 annual procedures in the U.S.

    NSPR
  2. SEC EDGAR

    8-K filing — InspireMD, Inc. (NSPR)

    Filed: 2026-09-21 AccNo: 0001493152-26-043488 Size: 314 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

    NSPR
  3. Benzinga Insights

    Full Transcript: InspireMD Q2 2026 Earnings Call

    InspireMD (NASDAQ:NSPR) reported second-quarter financial results on Monday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by Benzinga

    NSPR